Further, ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor-2 (VEGFR-2), has shown significant benefit on a specific subpopulation of HCC patients, with high baseline AFP level ≥ 400 ng/mL [16]. Here, AFP is linked to hepatocellular carcinoma.